Insights

Gathering insights about Minds…

Similar companies to Minds

Minds Tech Stack

Minds uses 8 technology products and services including Kubernetes, Cloudflare CDN, Cloudflare, and more. Explore Minds's tech stack below.

Kubernetes
Containerization
Cloudflare CDN
Content Delivery Network
Cloudflare
Content Management System
Module Federation
Development
Cart Functionality
E-commerce
Google Workspace
Email
ProtonMail
Email Hosting
TinyMCE
Rich Text Editors

Media & News

Why Bright Minds Biosciences Stock Topped the Market on Monday
Days after starting a new investigational program, it announced four appointments to its scientific advisory board. All of these professionals are experts in the affliction being targeted.
Nov 17, 2025 | www.fool.com
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on November 6, 2025 -- NEW YORK and VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today announced the addition of four global experts in Prader-Willi Syndrome (PWS) to its Scientific Advisory Board (SAB):
Nov 17, 2025 | www.globenewswire.com
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome -- -- Key Opinion Leaders (KOLs) participating on the call will include Theresa V. Strong, PhD., Jennifer L. Miller, MD, and Elizabeth Roof, H.S.P., M.A. -- -- Strong pre-clinical and clinical rationale supports potential of BMB 5-HT2C agonists to be the first on-target mechanism addressing both neuropsychiatric symptoms and hyperphagia -- NEW YORK and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today announced the initiation of its Prader-Willi Syndrome (PWS) program, and nomination of BMB-105 as a new clinical candidate. As part of the development program, Bright Minds will commence:
Nov 06, 2025 | www.globenewswire.com
Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable
Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Oct 15, 2025 | www.zacks.com
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade
The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sep 18, 2025 | www.zacks.com
Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?
The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sep 02, 2025 | www.zacks.com
STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
NEEDHAM, Mass. , Aug. 18, 2025 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Barth syndrome.
Aug 18, 2025 | www.prnewswire.com

Minds's Email Address Formats

Minds uses at least 1 format(s):

Minds Email Formats	Example	Percentage
First@minds.com	John@minds.com	47%
Last@minds.com	Doe@minds.com	4%
First.Last@minds.com	John.Doe@minds.com	2%
First@minds.com	John@minds.com	47%

Frequently Asked Questions

Where is Minds's headquarters located?

Minds's main headquarters is located at PO Box 7681, Wilton, CT 06897, US. The company has employees across 6 continents, including North AmericaAsiaSouth America.

What is Minds's stock symbol?

Minds is a publicly traded company; the company's stock symbol is DRUG.

What is Minds's official website and social media links?

Minds's official website is minds.com and has social profiles on LinkedIn Crunchbase.

What is Minds's NAICS code?

Minds's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Minds have currently?

As of October 2025, Minds has approximately 227 employees across 6 continents, including North AmericaAsiaSouth America. Key team members include Chief Executive Officer: D. C. W.Chief Executive Officer: B. O.Chief Executive Officer: B. O.. Explore Minds's employee directory with LeadIQ.

What industry does Minds belong to?

Minds operates in the Technology, Information and Internet industry.

What technology does Minds use?

Minds's tech stack includes KubernetesCloudflare CDNCloudflareModule FederationCart FunctionalityGoogle WorkspaceProtonMailTinyMCE.

What is Minds's email format?

Minds's email format typically follows the pattern of First@minds.com. Find more Minds email formats with LeadIQ.

How much funding has Minds raised to date?

As of October 2025, Minds has raised $10M in funding. The last funding round occurred on Jun 15, 2021 for $10M.

When was Minds founded?

Minds was founded in 2011.

Minds

Q: What is Minds's official website and social media links?

Minds's official website is minds.com. Minds has social profiles on LinkedIn.

Q: How many employees does Minds have currently?

Minds has approximately 227 employees.

Q: What technology does Minds use?

Minds's tech stack includes Webpack, Cloudflare Web Optimizations, Postman, Google Fonts API, Kubernetes.

Technology, Information and InternetUnited States201-500 Employees

Minds is open source and decentralized social networking software. We build social apps in minutes for brands, creators and organizations who want more ownership of their community spaces online. Our flagship social network Minds.com has grown to over 5 million members who are passionate about Internet freedom and digital rights.

Company Overview

Headquarters: PO Box 7681, Wilton, CT 06897, US
Website: minds.com
Stock Symbol: DRUG
NAICS Code: 5415 - Computer Systems Design and Related Services
Founded: 2011
Employees: 201-500

Media & News

Funding & Financials

$10M
Minds has raised a total of $10M of funding over 4 rounds. Their latest funding round was raised on Jun 15, 2021 in the amount of $10M.
$1M$10M
Minds's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$10M
Minds has raised a total of $10M of funding over 4 rounds. Their latest funding round was raised on Jun 15, 2021 in the amount of $10M.
$1M$10M
Minds's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Minds

Twitter

Telegram

Ello, PBC

Mastodon

Minds

Rumble

Sgrouples

LinkedIn

diaspora*

Parler

Steemit

Minds Tech Stack

Media & News

Why Bright Minds Biosciences Stock Topped the Market on Monday

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade

Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?

STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME

Minds's Email Address Formats

Frequently Asked Questions

Where is Minds's headquarters located?

What is Minds's stock symbol?

What is Minds's official website and social media links?

What is Minds's NAICS code?

How many employees does Minds have currently?

What industry does Minds belong to?

What technology does Minds use?

What is Minds's email format?

How much funding has Minds raised to date?

When was Minds founded?

Minds

Company Overview

Media & News

Why Bright Minds Biosciences Stock Topped the Market on Monday

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?